Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 6/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | OAT | P04181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447755 | 0.95 | PARP1 (0.42) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL4334172 | 0.95 | PARP1 (0.42) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL10954847 | 0.89 | PARP1 (0.37) | PARP1PARP15PARP10ALDH1A1MAPT | |
| SCHEMBL12475847 | 0.89 | ALDH1A1 (0.37) | PARP1PARP15PARP10DHODHALDH1A1 | |
| SCHEMBL252263 | 0.86 | DHODH (0.45) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL4447758 | 0.83 | ALDH1A1 (0.37) | PARP1PARP15PARP10ALDH1A1KDM4E | |
| SCHEMBL17024327 | 0.80 | DHODH (0.41) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL17024326 | 0.80 | DHODH (0.41) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL217840 | 0.80 | DHODH (0.41) | PARP1PARP15PARP10DHODHFABP4 | |
| SCHEMBL12491709 | 0.80 | DHODH (0.41) | PARP1PARP15PARP10DHODHFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531834-A1 | TREATMENT OF ULCERATIVE COLITIS COMPRISING VIDOFLUDIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Immunic AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023232884-A1 | TREATMENT OF ULCERATIVE COLITIS COMPRISING VIDOFLUDIMUS OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | IMMUNIC AG (DE) | 2023-12-07 | — | — | WO | disclosed |
| CN-108676076-A | The method for preparing guanosine cyclic mono-phosphate agonist | 辛纳吉制药公司 | 2018-10-19 | — | — | CN | disclosed |
| CN-107090016-A | The method for preparing guanosine cyclic mono-phosphate activator | 辛纳吉制药公司 | 2017-08-25 | — | — | CN | disclosed |
| US-8653138-B2 | Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC MG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120035175-A1 | Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | 4SC AG (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120029034-A1 | Novel calcium salts of Compound as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029034-A1 | Novel calcium salts of Compound as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | PPARD, PPARG, PPARA | PARP1 2501/4885PARP15 3232/4885PARP10 2828/4885 |
| US-20120035175-A1 | Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents | ARG1, CD14, RXRG | PARP1 2678/4885PARP15 3566/4885PARP10 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.